Pharmacotherapy of alcohol use disorders in the veterans health administration

Psychiatric Services

Volumn 61, Issue 4, 2010, Pages 392-398

  Harris, Alex H S ^a,b   Kivlahan, Daniel R ^c   Bowe, Thomas ^a,b   Humphreys, Keith N ^a,b  

^a CENTER FOR HEALTH CARE EVALUATION   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; DISULFIRAM; NALTREXONE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ALCOHOL ABUSE; ALCOHOLISM; ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH CARE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PSYCHOTHERAPY; TREATMENT DURATION; VETERAN;

EID: 77950814676     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/ps.2010.61.4.392     Document Type: Article

References (32)

1. Mark TL, Kassed CA, Vandivort-Warren R, et al: Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug and Alcohol Dependence 99:345-349, 2009
2. McLellan AT: What we need is a system: creating a responsive and effective substance abuse treatment system; in Rethinking Substance Abuse: What the Science Shows and What We Should Do About It. Edited by Miller WR. New York, Guilford, 2006
3. Heinrich CJ, Hill CJ: Role of state policies in the adoption of naltrexone for substance abuse treatment. Health Services Research 43:951-970, 2007
4. Mark TL, Kranzler HR, Poole VH, et al: Barriers to the use of medications to treat alcoholism. American Journal of Addiction 12:281-294, 2003
5. Mark TL, Kranzler HR, Song X, et al: Physicians' opinions about medications to treat alcoholism. Addiction 98:617-626, 2003
6. Oser CB, Roman PM: Organizational-level predictors of adoption across time: naltrexone in private substance-use disorders treatment centers. Journal of Studies on Alcohol and Drugs 68:852-861, 2007
7. Grant BF, Stinson FS, Dawson DA, et al: Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry 61:807-816, 2006
8. Hasin DS, Stinson FS, Ogburn E, et al: Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry 64:830-842, 2007
9. Mark T, Kassed C, Vandivort-Warren R: Medications for treating substance abuse: physician prescribing patterns and their implications. Presented at the Academy-Health Annual Research Meeting, Washington, DC, June 8-10, 2008
10. Substance Use Disorders Physician Performance Measurement Set. Chicago, American Medical Association and National Committee for Quality Assurance, 2008. Available at www.ama-assn.org/ama1/pub/upload/mm/370/sud-ws-final.pdf
11. Uniform Mental Health Services in VA Medical Centers and Clinics. VHA Handbook 1160.01. Washington, DC, Department of Veterans Affairs, Veterans Health Administration, 2008
12. VA/DoD Clinical Practice Guideline for Management of Substance Use Disorder (SUD): Guideline Summary. Washington, DC, Department of Veterans Affairs and Department of Defense, July 2009. Available at www.healthquality.va. gov/sud/sud-sum-v2-0.pdf
13. Hermos JA, Young MM, Gagnon DR, et al: Patterns of dispensed disulfiram and naltrexone for alcoholism treatment in a veteran patient population. Alcohol Clinical and Experimental Research 28:1229-1235, 2004
14. Kranzler HR, Stephenson JJ, Montejano L, et al: Persistence with oral naltrexone for alcohol treatment: implications for healthcare utilization. Addiction 103:1801-1808, 2008
15. VIReC Exploring Options for Researchers Needing Data on Race. Washington, DC, Department of Veterans Affairs, VA Information Resource Center, VIReC Data Issues Brief, Mar 2004. Available at www.virec.research.va.gov/references/ dataissuesbrief/2004/dib-0403.pdf
16. Krystal JH, Cramer JA, Krol WF, et al: Naltrexone in the treatment of alcohol dependence. New England Journal of Medicine 345:1734-1739, 2001
17. Gueorguieva R, Wu R, Pittman B, et al: New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. Biological Psychiatry 61:1290-1295, 2007
18. Anton RF, Oroszi G, O'Malley S, et al: An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Archives of General Psychiatry 65:135-144, 2008
19. Dufour M, Fuller RK: Alcohol in the elderly. Annual Review of Medicine 46:123-132, 1995
20. Council on Scientific Affairs, American Medical Association: Alcoholism in the elderly. JAMA 275:797-801, 1996
21. Krystal JH, Gueorguieva R, Cramer J, et al: Naltrexone is associated with reduced drinking by alcohol dependent patients receiving antidepressants for mood and anxiety symptoms: results from VA Cooperative Study No 425: "Naltrexone in the treatment of alcoholism." Alcohol Clinical and Experimental Research 32:85-91, 2008
22. Kinder LS, Bryson CL, Sun H, et al: Alcohol screening scores and all-cause mortality in male Veterans Affairs patients. Journal of Studies on Alcohol and Drugs 70:253-260, 2009
23. Wagner TH, Harris KM, Federman B, et al: Prevalence of substance use disorders among veterans and comparable non-veterans from the National Survey on Drug Use and Health. Psychological Services 4:149-157, 2007
24. Kranzler HR, Koob G, Gastfriend DR, et al: Advances in the pharmacotherapy of alcoholism: challenging misconceptions. Alcoholism, Clinical and Experimental Research 30:272-281, 2006
25. Saxon AJ, McCarty D: Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs. Pharmacology and Therapeutics 108:119-128, 2005
26. Ducharme LJ, Knudsen HK, Roman PM: Trends in the adoption of medications for alcohol dependence. Journal of Clinical Psychopharmacology 26(suppl 1):S13-S19, 2006
27. Thomas SE, Miller PM: Knowledge and attitudes about pharmacotherapy for alcoholism: a survey of counselors and administrators in community-based addiction treatment centres. Alcohol and Alcoholism 42:113-118, 2007
28. Thomas SE, Miller PM, Randall PK, et al: Improving acceptance of naltrexone in community addiction treatment centers: a pilot study. Journal of Substance Abuse Treatment 35:260-268, 2008
29. Oxman A, Thomson M, Davis D, et al: No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. Canadian Medical Association Journal 153:1423-1431, 1995
30. Forsetlund L, Bjorndal A, Rashidian A, et al: Continuing education meetings and workshops: effects on professional practice and health care outcomes. Cochrane Database of Systematic Reviews 2:CD003030, 2009
31. Roman PM, Johnson JA: Adoption and implementation of new technologies in substance abuse treatment. Journal of Substance Abuse Treatment 22:211-218, 2002
32. Fuller BE, Rieckmann T, McCarty D, et al: Adoption of naltrexone to treat alcohol dependence. Journal of Substance Abuse Treatment 28:273-280, 2005